Register for free to
view the full innovation profile.
Unlike the naturally occurring protein, Emtins offer potential utility as therapeutics.
About
The University of Tasmania collaborated with researchers in Denmark to identify novel peptide analogues of the naturally occurring protein Metallothionein (MT). MT is involved in endogenous multi-modal reparative processes associated with neurodegenerative and other indications. These peptides analogues (Emtins) appear to have the same mode of action to MT, promoting neural cell survival and regenerative growth. However, unlike the naturally occurring protein, Emtins offer potential utility as therapeutics. Value Proposition The University of Tasmania has sought patent protection for these novel peptide fragments across a range of therapeutic applications, including but not limited to Parkinson's, Alzheimer's or dementia. Under a separate defensive patent, the University of Tasmania has also protected MT. This duo of patents provides commercial partners with broad protection around therapeutic applications of MT.